- Home
- OSW vs ZYME Comparison
OSW vs ZYME Comparison
Compare OSW & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSW | ZYME |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | OSW | ZYME |
|---|---|---|
| Price | $20.56 | $22.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $23.67 | ★ $32.75 |
| AVG Volume (30 Days) | 642.6K | ★ 843.3K |
| Earning Date | 02-18-2026 | 03-04-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 40.79 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $936,080,000.00 | $134,481,000.00 |
| Revenue This Year | $8.65 | $63.10 |
| Revenue Next Year | $7.26 | $93.26 |
| P/E Ratio | $28.68 | ★ N/A |
| Revenue Growth | 7.27 | ★ 116.21 |
| 52 Week Low | $14.21 | $9.03 |
| 52 Week High | $23.49 | $28.49 |
Technical Indicators
Market Signals| Indicator | OSW | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 38.08 |
| Support Level | $19.23 | $22.00 |
| Resistance Level | $20.40 | $23.79 |
| Average True Range (ATR) | 0.75 | 0.88 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 45.18 | 3.90 |
Price Performance
Historical ComparisonAbout OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.